UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) March 30, 2006


Interpharm Holdings, Inc.
 
(Exact name of Registrant as specified in charter)

Delaware
0-22710
13-3673965
(State or other jurisdic-
(Commission
(IRS Employer
tion of incorporation)
File Number)
Identification No.)
     
     
75 Adams Avenue, Hauppauge, New York
11725
(Address of principal executive offices)
(Zip Code)

Registrant's telephone number, including area code: (631) 952-0214

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 


Item 5.02  Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

Effective immediately, Interpharm Holdings, Inc. has appointed Mr. Kenneth Cappel as its General Counsel.


Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  INTERPHARM HOLDINGS, INC. 
     
March 30, 2006
  
By:     /s/ George Aronson                         
   
George Aronson
   
Chief Financial Officer